Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130006/S110

GORE VIABAHN Endoprosthesis and GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface

W. L. Gore & Associates, Inc. · Decision date Oct 17, 2025

FDA DECISIONP130006/S110

What did the FDA decide?

FDA records P130006/S110 as a supplement to PMA P130006, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 17, 2025.

FDA approval order statement

implementation of an additional supplier of a raw material of the CBAS Heparin Surface
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 17, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P130006/S110
Regulatory pathway
PMA supplement
Product code
PFV
Decision code
OK30
Decision date
Oct 17, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment.

Product code
PFV
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P130006/S110 received

    Application receipt date recorded by FDA.

  2. P130006/S110 · FDA decision

    30-Day Notice

  3. P130006/S111 · Related supplement

    GORE VIABAHN Endoprosthesis, GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface

Timeline entries are records held by MedtechLedger for P130006. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130006

Product / regulatory recordCompanyPathwayDecision dateSource
W. L. Gore & Associates, Inc.PMA supplementMay 26, 2026FDA

Explore the linked device profile

Other records with product code PFV

Product / regulatory recordCompanyPathwayDecision dateSource
Bard Peripheral Vascular, Inc.PMA supplementJun 22, 2026FDA
Merit Medical Systems, Inc.PMA supplementJun 11, 2026FDA
Bard Peripheral Vascular, Inc.PMA supplementJun 10, 2026FDA
C.R. Bard, Inc.PMA supplementJun 10, 2026FDA
C.R. Bard, Inc.PMA supplementDec 16, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

W. L. Gore & Associates, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3250 W. Kiltie Ln., Flagstaff, AZ, 86001

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records